Financials

  • Market Capitalization 396.0492 M
  • Employee 77
  • Founded 1990
  • CEO N/A
  • Website www.lineagecell.com
  • Headquarter California, United States
  • FIGI BBG000G8RJY6
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益(基本EPS)
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-5.96
売上高対価格比率
26.4

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

ニュース